Table 1. The results from genetic detecting during treatment.
| Gene name | 2017.10.17 | 2018.3 | 2018.4.18 | 2018.4.22 | 2018.7.21 |
|---|---|---|---|---|---|
| EGFR exon 19 deletion mutations | 57.3% | 67.58% | Y | 49.93% | 61.51% |
| EGFR copy number amplification (CN) | 4.7 | 4.68 | – | 3.14 | 3.69 |
| TP53 non-shift deletion mutation in exon 5 | 34.05 | 76.73 | Y | 34.47 | 55.94 |
| RB1 frameshift mutation in exon 2 | 48.09 | 84.03 | – | 44.79 | 70.26 |
| MSH2 | – | – | Y | – | – |
| MSH6 missense mutation in exon 4 p. D904E | – | 26.59 | Y | – | – |
| PMS2 copy number amplification (CN) | – | 4.96 | – | 3.26 | 3.89 |
| TMB (Muts/Mb) | – | ≤10 | 15.32 | ≤10 | 9.5 |
Y, the result was positive; –, the result was negative. EGFR, epidermal growth factor receptor; CN, copy number; TMB, tumor mutational burden.